Startups
By testing the response of a patient’s own cancer cells against many treatment options, we help physicians and patients make truly informed personalized treatment decisions.
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 24, 2026 | USD 5.4 Million to advance Prevision Medicine’s functional precision oncology platform | Functional testing represents the next frontier in precision oncology. Prevision Medicine’s single-cell platform evaluates a patient’s living, tumor-derived cells against an extensive treatment library. By measuring direct cellular respons... |
| May 1, 2026 | Swiss startup days reveals Newcomers 2026 deep tech cohort | Newcomers is the pitching event reserved for early-stage startups at the Swiss startup days conference, with a focus on deep tech and applied tech ventures that have demonstrated early traction with a prototype or MVP. Selected startups pr... |
| Oct 2, 2025 | Life sciences companies make positive progress | At Synendos Therapeutics, topline results of the phase 1 clinical trial for its lead asset, SYT-510, a first-in-class inhibitor that modulates a newly identified drug target in the Endocannabinoid System that helps restore healthy brain fu... |
Reviews 0
FAQ about Prevision Medicine
What has the press written about Prevision Medicine?
Parsers VC has collected 4 articles mentioning Prevision Medicine, among them “USD 5.4 Million to advance Prevision Medicine’s functional precision oncology platform” (Sep 24, 2026) and “Swiss startup days reveals Newcomers 2026 deep tech cohort” (May 1, 2026).
Is Prevision Medicine still active?
Prevision Medicine is probably closed: its latest activity on Parsers VC dates from Sep 25, 2026.